OCGN: Ocugen Pharma Market Cap to Revenue

Symbol and logo of brand Ocugen Inc (OCGN)

The market capitalization-to-revenue ratio illustrates the asset's dynamics, where the 58.90 mark captures this metric. Ocugen, Inc. (OCGN) is developing gene therapy while awaiting FDA approval for its OCU400 drug. The company's environmental policy is based on laboratory emission filtration and energy efficiency. The current development vector relies on compliance with basic waste disposal norms and sustainable development standards.

Ocugen Corp (OCGN): Price-to-Revenue Ratio from 04/18/2024 to 11/15/2026

Analytical breakdowns for Ocugen Pharma (OCGN)

- stock price and consensus target price:
Share Price Ocugen|OCGN - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Ocugen, Inc.|OCGN - Real Price to Acquire Entire Company
- book value of equity indicators:
Net Assets per Share Ocugen|OCGN - Company Book Value|Market-to-Book Ratio ocugen.com|OCGN - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Ocugen, Inc.|OCGN - Long-Term Debt to Capital|Short-Term Indebtedness to Equity ocugen.com|OCGN - Company Debts|Debt to Book Value Ratio Ocugen Pharma|OCGN - Company Long-Term Debts|Company Short-Term Indebtedness Ocugen|Immediate Liquidity Ratio ocugen.com
- net income and valuation ratios data:
OCGN - Net Profit|Projected Future Earnings Ocugen, Inc.|OCGN - Price to Earnings Ratio|Projected Price to Earnings Ratio Ocugen Corp|OCGN - PEG Multiple|Enterprise Value to EBITDA Ratio Ocugen, Inc.|OCGN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Ocugen|OCGN - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year ocugen.com|OCGN - Earnings growth in current year|Expected net earnings per share growth next year Ocugen, Inc.
- total revenue and sales volume data:
OCGN - Company Revenue|Company Revenue Forecast Ocugen Corp|OCGN - Market Cap to Revenue|Forward Price to Sales Ocugen Pharma|OCGN - Sales Growth YoY (TTM)
Fundamental company analysis:Ocugen (OCGN)
Original product of Ocugen Corp

The P/S multiple determines the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of generated revenue within fundamental analysis. The P/S ratio dynamics reflect the dependence of Ocugen, Inc. (OCGN) capitalization on regulatory expectations, where the gap between price and actual sales highlights high financing risks in the absence of guaranteed commercial demand for its drugs.

Competing companies

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Beam Therapeutics Inc.|Price-to-Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Revenue Ratio|10x Genomics Inc - Market Cap to Revenue|NTLA (Intellia Therapeutics, Inc.) - Price-to-Sales Ratio|Stoke Corp - P/S Multiple|BLFS (BioLife) - Market Cap to Revenue Ratio|wavelifesciences.com (WVE) - Price-to-Revenue Ratio|MAZE - Price-to-Revenue Coefficient|SION (Sionna Therapeutics, Inc.) - P/S Multiple|Market Cap to Revenue Prime Medicine Corp (PRME)|P/S Multiple TSHA|P/S Multiple uniQure N.V. (QURE)|Price-to-Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc - P/S Multiple|PACB - P/S Multiple|BNTC (Benitec Corp) - Market Cap to Revenue|Price-to-Revenue Multiple Design Corp DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals|P/S Multiple 4D Molecular Therapeutics, Inc.|Price-to-Revenue Ratio Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple EDIT (Editas Medicine, Inc.)|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio